C-reactive protein (CRP) interacts with phosphorylcholine (PC), Fc receptors, complement factor C1q and cell nuclear constituents, yet its biological roles are insufficiently understood.
INTRODUCTION
The human complement system is composed of at least 30 soluble or membrane-associated proteins, and forms a core of the innate immune system. The classical pathway can be activated by target-bound antibodies, lipopolysaccharide, C-reactive protein (CRP) or DNAhistone complexes [1] . The alternative pathway can be triggered by the classical pathway or by direct contact with a variety of foreign molecules, protein aggregates/particles [2] and the lectin pathway is activated by mannose-binding lectin [3] . The physiological relevance of complement is demonstrated by recurrent infections in patients lacking certain components, as well as the overrepresentation of systemic lupus erythematosus (SLE) or SLE-like disease in individuals with deficiencies of the early complement factors [4] . On the other hand, in SLE as well as other inflammatory disorders, e.g. cardiovascular disease, rheumatoid arthritis and multiple sclerosis, complement activation may also contribute to the pathogenesis [2, 5, 6] .
Together with serum amyloid P component (SAP) and pentraxin-3, CRP belongs to the phylogenetically ancient and highly conserved family of pentraxins, which share a common structure with five identical subunits linked by weak non-covalent bonds and arranged in cyclic symmetry. Due to its dramatic rise within the initial 24 to 72 hours in response to proinflammatory stimuli or tissue damage, CRP is an important marker of ongoing systemic inflammation [7] . Circulating CRP is essentially derived from hepatocytes, but small amounts may also be produced locally by other cells [8] . The synthesis is mainly regulated at the transcriptional level through IL-6-and IL-1-directed induction of the CRP gene, located on the long arm of chromosome 1, by activation of NF-B and transcriptional factor NF-IL-6/CAAT-enhancer binding protein (C/EBP) family members C/EBP and C/EBP [7, 9] .
The calcium-dependent binding of CRP to phosphorylcholine (PC) exposed on bacterial cell walls, damaged cell membranes or apoptotic blebs, offers an explanation to the antibody-like properties of CRP, which is opsonizing by its Fc gamma receptor (FcR) affinity [7, 8, 10, 11] . Minor CRP elevations have been shown to reflect a low-grade vascular inflammation, and to predict coronary events in patients with angina pectoris as well as in apparently healthy subjects [8, 12] . More substantial elevations of circulating CRP is a useful sign of systemic inflammation, e.g. in bacterial infections. In SLE, however, the CRP response is often limited or absent despite high disease activity and high circulating IL-6 levels [13] .
Activation of the complement cascade is regarded as one of the main physiological functions of CRP, originally described by Kaplan and Volanakis who demonstrated consumption of hemolytic complement components in acute-phase sera mixed with pneumococcal Cpolysaccharide, and by Siegel et al. using CRP-protamine complexes [14, 15] . In the presence of calcium, each CRP subunit is able to complex with a PC-containing structure. Since all subunits of the CRP pentamer are targeted in the same direction, a recognition face is formed on the PC-bearing surface. C1q binds to the opposite face of the pentamer, thereby inducing complement activation via formation of the classical C3 convertase, which assembles in a fashion similar to that initiated by antibody-antigen complexes [7] . In contrast to IgM-and IgG-mediated complement activation, the CRP-mediated activation appears to be essentially limited to the initial stage involving C1-C4 with less consumption of the terminal complement proteins C5-C9 [16] . The difference in complement activation by CRP and immune complexes (ICs) has been suggested to be due to a stronger direct interaction between CRP and factor H, leading to inhibition of the alternative complement pathway C3 and C5 convertases [17, 18] .
Concomitantly with the release of acute phase reactants, neutrophils infiltrating an inflammatory locus may become activated, discharging hydrolytic enzymes and reactive oxygen species, and contributing to an acidic local microenvironment. Under these conditions in vitro, there is evidence that CRP undergoes structural changes with dissociation of its subunits [19, 20] . These monomeric CRP subunits (mCRP) expose epitopes not present on pentameric CRP and display properties distinct from those of native CRP. For instance, mCRP has been shown to interact with ICs, affect neutrophil-platelet adhesion and neutrophil aggregation, augment platelet activation and stimulate platelet generation [21] [22] [23] [24] . In contrast to native CRP, the dissociation of monomers has been suggested to mediate proatherosclerotic effects on human endothelial cells [12] . However, the complement activating properties of mCRP have not yet been fully elucidated [25, 26] .
The aim of the present study was to analyze CRP-induced complement activation on model PC-surfaces with focus on protein deposition over time and CRP concentration in serum.
MATERIALS AND METHODS

Preparation of aminated silicon
Due to its even optical properties during ellipsometry, silicon was chosen as the model substrate. The wafers were cleaved in the (100) crystal direction, cleaned in a basic peroxide solution of 5:1:1 parts of distilled water (Milli-Q quality), hydrogen peroxide (30% v/v), and NH 4 OH (25% v/v), respectively, at 80˚ C for 5 minutes [27] . The wafers were rinsed five times in distilled water followed by washing with an acidic peroxide solution with 6:1:1 parts of distilled water, hydrogen peroxide (25% v/v) and hydrogen chloride (37% v/v), at 80˚ C for 5 minutes [28] . Finally, the surfaces were rinsed three times in distilled water and dried in flowing nitrogen. This treatment resulted in a thin hydrated silicon dioxide layer with an advancing water contact angle of less than five degrees. The surfaces were placed in a low vacuum chamber at 6 mtorr pressure and 200 l 3-aminopropyl triethoxy silane (APTES; Sigma-Aldrich, St. Louis, USA) was let into the chamber and evaporated. The APTES coated surfaces were heat-treated inside the chamber at 60° C for 10 minutes, and at 150° C for 60 minutes. The prepared slides were rinsed three times in xylene (Merck GmbH, Darmstadt, Germany) at room temperature, and stored in xylene until use within 8 hours. The static water contact angle (θ) of aminated silicon was <45 (n=5; Rame-Hart goniometer, USA).
Preparation of phosphorylcholine surfaces
6% glutaraldehyde (GA) in phosphate buffered physiological saline (PBS), pH 9, was used to link the first layer of fibrinogen (Haemochrom Diagnostica, Mölndal, Sweden) onto APTES on silicon. The surfaces were incubated with GA for 30 minutes followed by extensive rinsing in distilled water. The APTES-GA samples were incubated for 30 minutes at room conditions Since mCRP has poor affinity for PC [29] , approximately 13 Å mCRP was pre-immobilized by EDC:NHS chemistry on two layers of fibrinogen on APTES-GA as described above.
Reagents
Aqueous solutions (20 mM Tris-HCl, pH 7.8-8.2, containing 280 mM NaCl, 5 mM calcium chloride, 0.1% sodium azide) of at least 99% pure human pentameric plasma CRP (stock concentration 2.5 mg/mL; Sigma-Aldrich) or human serum from 7 individuals (CRP levels and complement profile given in Table 1 ) were used as source of CRP. The CRP concentrations were determined using high sensitivity turbidimetry technique (Bayer HealthCare, Advia 1650, NY, USA). Irreversible dissociation of purified CRP (mCRP) was obtained by acid-treatment (pH 2.0) of pentameric CRP prior to neutralization [19] .
Fresh serum samples were stored at 4° C or frozen at -70° C within 3 hours for less than 5
days. In some experiments, CRP was added to sera and plasma samples to final concentrations up to 500 mg/L, and allowed between 5 to 60 minutes of pre-equilibration at room temperature. In other experiments sera were serially diluted in 3-fold steps in VB -containing sera.
Antibodies
The following antibodies were used: rabbit anti-human IgG, rabbit anti-human C1q, rabbit anti-human C3c, rabbit anti-human C4, rabbit anti-human fibrinogen, rabbit anti-human C- 
Ellipsometry
The thickness of the organic layers on silicon substrates was determined by null ellipsometry, which is a highly sensitive optical method with a practical resolution during protein adsorption measurements of about 1 Å [28, 31] . The measurements yielded two angles,  and , which were used to iterate the protein film thickness. The serum and complement activation experiments (n≥5) were performed as follows. Silicon samples of size 10x5 mm with immobilized PC were placed in a 1.5 ml plastic incubation trough containing CRP-enriched or unmodified serum. In other experiments the sera were diluted in VB 2+ -buffer.
The incubation times varied between 1 to 60 minutes and all experiments were performed at 37° C. Some of the serum-incubated surfaces were rinsed in VB 2+ -buffer and distilled water, dried in flowing nitrogen and the total serum deposition quantified. The other-serum incubated surfaces were rinsed in VB 2+ alone, and without drying transferred to antibody solutions (1:50 dilutions in VB 2+ -buffer) and incubated for 30 minutes at 20° C. The surfaces were finally rinsed in distilled water, dried as described above, and the thicknesses determined. The Auto-Ell III ellipsometer (Rudolph Research, Fairfield, NJ, USA) was programmed for measurements on silicon, and this option was used. The protein film thickness was calculated according to the McCrackin evaluation algorithm [32] and the adsorbed amount per unit area calculated by De Feijter's formula [33] . The refractive indices used were 1.335 and 1.465 for the buffer and the adsorbed APTES and proteins, respectively [34, 35] . One nanometer in thickness of dried deposited organic film equals approximately 120 ng/cm 2 in mass [36] .
Adsorption assay and RID
Increasing amounts of commercial CRP (Sigma-Aldrich) were added to a human normocomplementemic low-CRP serum sample (sample 1, Table 1 ) resulting in six tubes with different CRP concentrations (0, 50, 100, 150, 250 and 500 mg/L) and a volume of 0.5 mL, respectively. 50 µL of polyclonal anti-CRP antibody (DAKO) was added, the tubes were mixed and equilibrated for 15 minutes at room temperature. 100 µL of protein-G sepharose (GE Healthcare, Uppsala, Sweden) was added and the tubes mixed again. The tubes were then allowed to sediment before centrifugation during 10 minutes at 850 x g. The supernatants
were transferred to new tubes.
Each sample was applied to commercial RID kits (Binding Site, Birmingham, UK) measuring C1q, C2 and C4. The enclosed protocols were followed. Two independent readers evaluated the results. The results are presented as percentage of a control serum, which was exposed to buffer alone instead of CRP solution but otherwise treated exactly as the other samples.
Statistics
The ellipsometric data are presented as mean values ± SEM of at least five independent experiments where each experiment was the mean value of five measurements. The RID data originate from three separate experiments in duplicate. Evaluation was performed using the two-tailed Student's t-test and the conventional significance levels of p<0.05, p<0.01 and p<0.001 were used.
Ethics
Informed consent was obtained from each patient and the study protocol was approved by the ethics committee at Linköping University.
RESULTS
Complement activation on PC-and IgG-coated surfaces
In order to compare complement activation on IgG-versus (vs) PC-coated surfaces, IgG was adsorbed to hydrophobized silicon and PC-KLH immobilized to pre-fabricated cross-linked fibrinogen layers. The surfaces were subsequently incubated for 0 to 60 minutes in normal serum (s-CRP 4 mg/L) with/without EGTA, or in normal serum supplemented with CRP (s-CRP 75 mg/L). Figure 1a illustrates the total serum protein deposition onto the different surfaces whereas 1b shows anti-C3c-binding after the serum incubations in each case.
Apparently, the IgG-coated surfaces activated the classical pathway strongly, followed by activation of the alternative pathway (effector pathway) in normal serum. Previously, we have
shown that the total serum protein deposition is dominated by surface C3b and its degradation fragments [36] . The amount was larger on IgG than on PC-surfaces and increased steadily throughout the 60 minutes incubation. Upon inhibition of the classical pathway by calcium chelation, the IgG-coated surfaces showed an approximately 10 minutes delay until serum protein begun to deposit, and now only via the alternative pathway. The deposited amounts increased in this case rapidly during alternative activation after 30-60 minutes of incubation [36] . The total serum protein deposition from normal serum (s-CRP 4 mg/L) was significantly lower onto PC-KLH-surfaces than onto IgG-surfaces, and could only be moderately increased 
Spontaneous adsorption of CRP on silicon
Very low amounts of anti-CRP bound to hydrophilic and hydrophobic reference surfaces after incubations in CRP-containing sera or plasma. The obvious indication is that, independent of the CRP concentration, hydrophilic negatively charged surfaces and hydrophobic surfaces per se possess low attraction to serum CRP, and hence induce low complement activation during elevated CRP conditions.
CRP levels higher than 300 mg/L inhibit complement activation on PC
Plasma and sera were prepared from blood of five individuals displaying elevated CRP levels, ranging from 106 to 420 mg/L ( Table 1 ). The total serum protein ( Figure 3a ) and anti-C3c The results from patient sera and plasma urged us to make experiments with CRPsupplemented sera. Figure 4a shows the increase in anti-C3c accumulation on top of the serum layer was most dramatic in the s-CRP interval between 4 to 10 mg/L, i.e. levels that in numerous studies have been shown to predict coronary events [8, 12] . The largest amounts of anti-C3c bound to surfaces exposed to serum with s-CRP ≈150 mg/L, whereas virtually no anti-C3c bound to surfaces exposed to serum with s-CRP >300 mg/L (Figure 4a ). The 
Fluid-phase interaction between CRP and C1q
We evaluated the possibility of fluid-phase interaction between CRP and one or more of the classical complement components as an underlying mechanism of the powerful inhibition on complement activation seen when high CRP concentrations were used. A normocomplementemic low-CRP serum was supplemented with increasing amounts of CRP.
After equilibration, CRP was captured with a polyclonal antibody and eliminated by protein-G sepharose. C1q, C2 and C4 were measured in the supernatants with radial immunodiffusion (RID). Less C1q was detected with increasing concentration of CRP whereas C2 and C4 were not affected at all (Figure 4c ).
DISCUSSION
Although it is known since 75 years that CRP is a major acute phase protein with a variety of biological activities, its physiological/pathophysiological roles remain unclear. One of the first identified properties of native CRP was its ability to activate the complement cascade by sequestration of C1q. In previous studies on CRP-complement interactions, indirect techniques, such as hemolytic activity [14, 15] , enzyme immunoassays [37] or immunohistochemistry [38] have been used. In the present study, we chose null ellipsometry to analyze the CRP-mediated complement deposition onto model PC-surfaces, a method that is direct, non-destructive, quantitative and allows the detection of early transient actors of the classical pathway, e.g. C1q, at interfaces with low serum dilutions and short time serum incubations [28, 31, 36] . Ellipsometry allows the detection of surface-adsorbed protein layers with a practical resolution of about 1 Å in biological environments with sensitivity similar to radioimmunoassays [35, 36] . Herein, we demonstrate classical activation of the complement system by CRP that interacts with surface-bound PC. The main indications for actual activation are the increasing protein deposition from normal and EGTA sera with added CRP (Figure 1a) as well as the concomitant surface binding of C1q and C3 in the serum dilution series (Figure 2b ).
Numerous studies have recognized an association between a minor elevation of CRP and future cardiovascular disease. Furthermore, there is considerable evidence suggesting that complement activation occurs in atherosclerotic lesions [2, 38] . In addition, elevation of the highly pro-inflammatory complement component C5a has been reported to increase the risk of cardiovascular events in patients with advanced atherosclerosis [39] . In the present study, we show that purified CRP and CRP in patient sera have similar capacity to activate complement on surface immobilized PC in a dose-dependent manner. Most interestingly, CRP proved to be a powerful complement activator even at concentrations below 10 mg/L (insert, Figure 4a ). This finding has implications both for the normal innate immune homeostasis and for cardiovascular disease where high sensitivity analysis of CRP is nowadays a widely used risk marker.
Our findings are in line with reports suggesting that the CRP-mediated complement activation on PC proceeds via the classical pathway [16] [17] [18] 25] . CRP-mediated complement activation could contribute to chronic inflammatory reactions in atherosclerosis and rheumatic diseases or represent an anti-inflammatory response that limits the deleterious effects of otherwise complete complement cascade. Possibly, the presence of PC-expressing structures, such as oxidized low-density lipoprotein (LDL), bacteria and apoptotic cells in the vascular environment induces generation of CRP, which together with C3 fragments opsonize the structures and facilitate their removal by phagocytes [40] . In support of this, CRP, LDL and complement factors have been shown to co-localize in early atherosclerotic lesions [38] .
In vitro studies have suggested that CRP binds factor H, a serum protein binding to immobilized C3b and inhibiting the alternative complement pathway, thereby regulating the complement activation and providing a possible explanation to the prevention of terminal complement complex formation [16] [17] [18] 41] . In contrast to many previous studies using purified proteins, we used complete serum. The antibody deposition pattern illustrated for the 106 mg/L serum in 2b suggests the involvement of both IgG and C1q during the initiation of the activation process whereas low but detectable levels of anti-factor H also bound onto this surface. The involvement of anti-PC antibodies can be excluded since no deposition of IgG occurred with any of the sera at CRP concentrations below 4 mg/L.
Very intriguingly, a dramatic fall in C1q-mediated complement activation occurred at high CRP levels, both in CRP-supplemented serum (s-CRP >150 mg/L; Figure 4a ) and in high-CRP patient sera (s-CRP >300 mg/L; Figure 3 ). This phenomenon, which has not been described previously, urged us to evaluate the hypothesis that soluble CRP prevents classical complement on surfaces by fluid phase consumption. Indeed, this was substantiated by an inverse relationship between CRP concentration and C1q level, whereas no CRP-interactions were found with C2 or C4 (Figure 4c ). Thus, we suggest that CRP binds C1q in fluid-phase and may have a dual role in classical activation by restricting potential damage on tissue surfaces in acute phase sera with high CRP levels. Lack of adequate CRP-mediated complement activation could possibly contribute to IC-mediated tissue damage in SLE [41, 42] , where the CRP response often appears to be lacking or is in disharmony with other acute phase reactions [43] . Interestingly, CRP supplementation to mice with lupus nephritis induces a sustained remission and prologs the survival [44] . We have previously reported the occurrence of autoantibodies to mCRP in SLE [45] . Although this does not explain the deficient CRP-reaction in SLE, it correlates to disease activity and may have relevance to the pathogenetic process [8, 46] .
Monomeric CRP has poor solubility in aqueous media but is found in normal vascular tissues as well as at sites of inflammation [8, 20] . We prepared mCRP by acid treatment and the capacity of mCRP to activate complement was investigated in comparison with native pentameric CRP. A previous study by Miyazawa and Inoue showed that the pH optimum for CRP-mediated complement activation was 6.3, which however, is not low enough to cause complete dissociation of pentamers to monomers [47] . Vaith and coworkers studied complement activation on HEp-2 cells and showed that mCRP binds distinct filamentous cytoplasmic structures but was not followed by deposition of complement components [26] .
Our results support the hypothesis that immobilized mCRP may activate the complement system. The reason for previous studies failing to display the deposition of C3 onto mCRP may be found in difficulties to obtain a reproducible deposition of anti-C3 after serum incubation. Similarly to our findings, a recent study by Ji et al. using mCRP indicated different effects on classical activation dependent on whether mCRP was in fluid-phase or bound to C1q [48] .
To conclude, we present new in vitro data on CRP-mediated C1q-dependent complement activation on surfaces. Complement is activated already at low CRP levels with a concentration-dependent increase of C3 surface deposition up to a CRP level of approximately 150 mg/L, followed by a marked down-regulation of C3 deposition at higher CRP concentrations. We suggest that the underlying mechanism to this phenomenon depends on fluid-phase interaction between CRP and C1q. An adequate CRP-response in acute inflammation may therefore be essential for normal immune homeostasis, cardiovascular disease and the pathogenesis of many inflammatory conditions. 
